News & Events
This will take effect December 1, 2012
Overview and Clinical Utility:
PathGroup’s Elizabethtown Patient Service Center will be moving from its current address (suite location) to a new address (suite location) effective December 1, 2012. Contact information and operational hours remain unchanged.
Click Here to read more.
This will take effect October 26, 2012
Overview and Clinical Utility:
The Cervical DNA Dtex testing process has recently been improved and enhanced. These improvements resulted in a lower abnormal cell threshold for test positivity as well as the establishment of a new threshold for test positivity based on excessive tetraploidy, as follows:
Click Here to read more.
Brentwood, Tenn. (September 30, 2012) – PathGroup, a leading provider of anatomic, clinical and molecular pathology services, launched an updated website today, www.pathgroup.com. The new site comes after PathGroup unveiled, earlier this year, a new brand identity to include a revised logo and tagline; illustrating a contemporary identity and vision as the company adapts in an ever-changing healthcare environment. The redesigned site further demonstrates PathGroup’s industry expertise, breadth of capabilities, and will serve as a resource for customers and patients.
“Launching a refreshed identity as we expand into new markets will enable us to effectively communicate the central focus of PathGroup – to exceed the expectations of our clients and their patients,” said Richard Halstead, Senior Vice President and Chief Marketing Officer for PathGroup. “Although this is a new look for PathGroup, the core foundation of the organization remains focused on providing industry leading anatomic, clinical and molecular pathology services.”
As one of the largest, private providers of pathology services in the United States, PathGroup continues to expand its service offering through organic growth initiatives and strategic merger and acquisitions. With over 45 years of experience providing the highest quality services, PathGroup has over 700 employees and more than 70 pathologists representing every sub-specialty. The company’s longevity can be attributed to consistently exceeding the expectations of clients and patients. Direct access to PathGroup’s team of dedicated pathologists is a central focus of the organization, leading to better client relations and ultimately better patient outcomes. This new identity and user-friendly website are reflective of that open culture.
“This is an exciting time for PathGroup and the clients we provide service to,” said Ben Davis, MD, PathGroup’s Chairman, President and CEO. “We will continue to provide high quality care and evolve our organization as the healthcare industry changes. Our goal is to meet the needs of those we provide services for, with a physician centered approach that is keenly focused on driving better patient outcomes. Staying at the forefront of advances in laboratory medicine is a critical component.”
About PathGroup
Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit www.pathgroup.com
This will take effect October 1, 2012
Overview and Clinical Utility:
Effective October 1, 2012, Syphilis treponemal antibody screening will be performed on the Diasorin Liaison XL using one-step chemiluminescence immunoassay. The presence of antibodies to Treponema pallidum specific antigen, in conjunction with non-treponemal laboratory tests and clinical findings, may aid in the diagnosis of syphilis infection.
Click Here to read more.
This will take effect October 1, 2012
Overview and Clinical Utility:
Effective October 1, 2012, Vitamin D 25 Hydroxy will be performed on the Diasorin Liaison XL using chemiluminescent immunoassay. Vitamin D testing is used in the assessment of vitamin D sufficiency. Assay results should be used in conjunction with other clinical or laboratory data to assist the clinician in making individual patient management decisions.
Click Here to read more.
This will take effect September 24, 2012
Overview and Clinical Utility:
The Kleihauer-Betke Fetal Stain has been discontinued and replaced with Fetal Cell Assay by Flow Cytometry as the routine method to assess fetal-maternal hemorrhage quantification and recommended RhIG dosage.
The traditional slide based Kleihauer-Betke test is a time consuming method with high rates of inter-observer result variation and suboptimal precision. A more accurate, improved methodology is achieved via the Fetal Cell Assay by Flow Cytometry.
Click Here to read more.
This will take effect September 24, 2012
Overview and Clinical Utility:
Effective Monday, September 24, 2012, PathGroup Labs will offer a nine (9) panel urine drug screen in which all positive results will automatically reflex for confirmation testing. The test code for this new drug screen is USDC. The UDSL drug screen will continue to be available and orderable.
Click Here to read more.
Teaneck, NJ, (September 18, 2012) – NeTLIMS™ NJ, LLC, a provider of advanced Laboratory Information Systems (LIS), announced today that PathGroup, a provider of comprehensive anatomic, clinical and molecular pathology services based in Nashville, Tennessee, has selected the company’s AutoLims® advanced laboratory information system.
PathGroup works with more than 70 hospitals and thousands of group practices across the United States. Founded in 1965, the company has over 700 employees and more than 70 pathologists representing every sub-specialty. PathGroup will be utilizing AutoLims for its core lab, microbiology and genetics, allowing the company to maximize its productivity, efficiency and profitability through technological superiority, accuracy, ease of use and careful attention to customer needs.
“We chose to implement an LIS that would allow us to continue to deliver high quality service our customers have come to expect while streamlining our workflow,” said Ben Davis, M.D., President, Chairman and CEO for PathGroup. “The AutoLims product suite is a comprehensive tool that provides support from requisition to results and is customizable to meet our specific needs.”
AutoLims is a powerful and intuitive, easy-to-install LIS that covers all aspects of a clinical lab’s operation while providing lightning-fast responsiveness. It is comprised of a broad suite of very scalable and flexible advanced software modules that share the same underlying infrastructure, which can be easily and effectively adapted to support the full spectrum of IT needs of both hospital and commercial laboratories.
“The advanced architecture and design of AutoLims include the flexibility and power the laboratory information systems of this era must have to address the ever-evolving requirements of today’s laboratory,” remarked Ephraim Brand, President and Chief Executive Officer of NeTLIMS. “These features and the openness of the system will allow PathGroup to continue to grow and provide the same high quality of service its customers have come to expect.”
About PathGroup
Founded in 1965, PathGroup has evolved into a premier provider of anatomic, clinical and molecular pathology services. Privately held and physician centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit www.pathgroup.com.
About NeTLIMS NJ, LLC
NeTLIMS develops, markets and supports the AutoLIMS product suite. Since 1996, AutoLIMS has been powering hundreds of medium to very large clinical laboratories in hospitals and commercial laboratories worldwide. NeTLIMS customers include Quest Diagnostics, leading large (over 1,000 beds) state-of-the-art hospitals, HMOs (including Clalit Health Services – the world’s second largest HMO) and hundreds of laboratory installations, both nationally and globally. Simply powerful – AutoLIMS is lightning fast and extremely intuitive. AutoLIMS supports the complete needs of all types of clinical laboratories, from an individual lab specialty to a network of laboratories with multiple expertise. A perfect combination of excellent client services, cutting edge technology, unparalleled customizability and extendibility allows AutoLIMS to provide state-of-the-art solutions for all disciplines inside the laboratory and for all stages of the testing process. For additional information, please see: http://www.netlims.com.
This will take effect July 16, 2012
Overview and Clinical Utility:
Effective July 16, 2012, Rubella IgM antibody testing will be performed in house on the Bioplex 2200 using a multiplex flow immunoassay methodology. Rubella IgM (German measles) is a viral infection with worldwide distribution. Testing immediately post-exposure is of no value without a later convalescent specimen. While the presence of IgM antibodies suggests current or recent infection, low levels of IgM antibodies may occasionally persist for more than 12 months post-infection or immunization.
Click Here to read more.
This will take effect July 16, 2012
Overview and Clinical Utility:
Effective July 16, 2012, Cytomegalovirus (CMV) IgM antibody testing will be performed on the Bioplex 2200 using a multiplex flow immunoassay methodology. CMV IgM is for the detection of human IgM antibodies to cytomegalovirus virus in human serum, as an aid in the determination of current or recent CMV infection.
Click Here to read more.
